AAN 2021 | Population-based studies are needed for patients with MS & COVID-19
Afagh Garjani
• 26 Apr 2021
Afagh Garjani, MD, Nottingham University Hospitals NHS Trust, Nottingham, UK, talks on the need for population-based studies to determine the true extent of the effects of SARS-CoV-2 infection on patients with multiple sclerosis (MS). Investigations need to assess both clinician-reported COVID-19 cases of hospitalized patients and self-reported cases from patients with MS living in the community. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.
Disclosures
Dr Garjani reports the following disclosures:
Research support: UK MS Society
Speaker honorarium: MS Academy
Travel support: Novartis
